Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (12339)	6/9/2003 4:00:55 PM
From: Eagle	Respond to of 48461

oh, believe me, i have never forgotten that i owe you some scotch --i am just never in US to get it done--will one day--should send you some of the local serbia stuff, slivovica, but only if you want to quit alcohol some day

To: Bucky Katt who wrote (12339)	6/9/2003 4:25:49 PM
From: Vegas	Read Replies (1) \| Respond to of 48461

Only problem is what to do with all the profits? Nothing left thats not up 50-100% (or more) already. Where are the rats?????????

To: Bucky Katt who wrote (12339)	6/9/2003 4:35:46 PM
From: Silver_Bullet	Respond to of 48461

The previous news about collaboration with Stanford and Cancer was enough to make ASTM a long term hold. Any good news to come of this and this stock easily becomes a mega mega gainer even from this level. *********** ANN ARBOR, Mich., May 30 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has entered into a collaborative agreement with Stanford University (Stanford) for a new therapeutic approach for cancer therapy. The collaboration will combine Aastrom's patented single-pass perfusion (SPP) cell production technology with Stanford's Cytokine Induced Killer (CIK) cell technology to produce cells designed to trigger an immune system attack on a patient's tumor cells. ************ FT